APLS Q2 2024 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$200M+110.3% YoY

Gross Profit

$176M88.2% margin

Operating Income

-$29M-14.7% margin

Net Income

-$38M-18.9% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+15.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$904M

Total Liabilities

$640M

Stockholders' Equity

$264M

Cash & Equivalents

$360M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$200M	$95M	+110.3%
Gross Profit	$176M	$87M	+103.4%
Operating Income	-$29M	-$120M	+75.6%
Net Income	-$38M	-$122M	+69.1%

Revenue Segments

Product

$179M90%

Licensing And Other Revenue

$21M10%